NEWS HIGHLIGHTS
Published Studies Related to Famvir (Famciclovir)
Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance. [2009.02]
BACKGROUND: Episodic therapy of genital herpes is usually recommended for patients with infrequent symptomatic recurrences and where transmission is not a concern. While shorter courses are as effective as standard 5-day regimens, it is unknown whether abbreviated therapy has detrimental effects on natural history and the development of antiviral resistance. OBJECTIVES: To assess time to next recurrence and development of antiviral resistance in patients with recurrent genital herpes treated with either single-day famciclovir (1 g twice-daily) or 3-day valacyclovir (500 mg twice-daily)... CONCLUSION: Treatment with single-day famciclovir for recurrent genital herpes did not shorten the time to the next recurrence. Drug resistance to penciclovir continues to be a rare event in immunocompetent patients.
Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. [2007.11]
OBJECTIVE: To investigate penciclovir pharmacokinetics following single and multiple oral administrations of famciclovir to cats.Famciclovir dosages of 15 mg/kg administered every 8 hours to cats are unlikely to result in plasma penciclovir concentrations with activity against feline herpesvirus-1.
Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. [2006.09]
BACKGROUND: Daily antiviral therapy with famciclovir and valacyclovir has been shown to be effective in reducing both symptomatic and asymptomatic reactivation of herpes simplex virus type 2 (HSV-2) when compared to placebo. However, few comparative studies between the 2 antivirals have been performed. OBJECTIVES: To compare the clinical and virologic effects of famciclovir and valacyclovir administered as daily suppressive therapy for persons with genital herpes... CONCLUSION: Valacyclovir appear to be somewhat better than famciclovir for suppression of genital herpes and associated shedding. Further comparative trials of antiviral drugs for various indications should be performed as acyclovir and penciclovir appear to have different ability to abrogate HSV reactivation.
Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. [2006.07]
BACKGROUND: The brief period of viral replication in recurrent herpes labialis lesions suggests shorter therapeutic regimens are a logical episodic treatment strategy. OBJECTIVE: We sought to assess the efficacy and safety of single-dose and single-day famciclovir treatments... CONCLUSION: Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.
Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. [2006.01.01]
BACKGROUND: Orally administered antiviral therapy for genital herpes improves the time to lesion healing and resolves symptoms during an outbreak. Although traditional therapy for a recurrent episode for healthy adults has consisted of twice-daily dosing for 5 days, recent studies have indicated that shorter courses of antiviral therapy are effective. This study was conducted to assess the efficacy and safety of a patient-initiated, single-day regimen of famciclovir therapy, compared with placebo, in immunocompetent adult patients with recurrent genital herpes... CONCLUSIONS: A single-day regimen of patient-initiated famciclovir treatment was well tolerated and safe, and the healing of recurrent genital herpes lesions occurred approximately 2 days faster than with placebo. Moreover, single-day famciclovir treatment stopped the development or progression of lesions beyond the papule stage. This convenient single-day regimen has the potential for improving patient compliance and satisfaction with therapy.
Clinical Trials Related to Famvir (Famciclovir)
Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection [Completed]
Herpes simplex virus causes cold sores (fever blisters) and can lead to painful lesions in
the mouth in healthy children. Children with impaired immune systems might develop severe
complications. Famciclovir is a drug approved to treat herpes simplex and varicella zoster
infection in adults. This study will evaluate the safety and blood levels of a new pediatric
formulation of Famvir in children 1-12 years of age.
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes [Completed]
This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare
the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed
by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in
patients with active recurrent genital herpes.
This study is not recruiting patients in the United States.
Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection [Completed]
Varicella zoster virus causes chickenpox in children and shingles in adults. Chickenpox is
usually a self-limiting illness characterized by fever and a rash. Serious complications can
include secondary bacterial infections, pneumonia, and encephalitis. Anti-viral treatment is
not a standard of care in immunocompetent children, but is recommended whenever a risk of
complication exists. This study will evaluate the safety and blood levels of a new
formulation of famciclovir in children 1-12 years of age.
Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection [Recruiting]
This study will evaluate the acceptability and safety of famciclovir in infants with herpes
simplex infection
A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis [Completed]
The study is designed to assess the efficacy and safety of patient-initiated therapy with
famciclovir 1500 mg o. d. or 750 mg b. i.d. for one day treatment in adult men and women with
recurrent herpes labialis
|
